These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 23175443)

  • 1. Oncogenic FGFR3 gene fusions in bladder cancer.
    Williams SV; Hurst CD; Knowles MA
    Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Satoh Y; Ishii N; Aoki M
    Mol Cancer Ther; 2015 Mar; 14(3):704-12. PubMed ID: 25589496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
    Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
    Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
    Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
    Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle.
    Sarkar S; Ryan EL; Royle SJ
    Open Biol; 2017 Aug; 7(8):. PubMed ID: 28855393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
    BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
    Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
    PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
    Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
    Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
    Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
    J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
    Gött H; Uhl E
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration.
    Banella C; Ginevrino M; Catalano G; Fabiani E; Falconi G; Divona M; Curzi P; Panetta P; Voso MT; Noguera NI
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):163-168. PubMed ID: 32199932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A metabolic function of FGFR3-TACC3 gene fusions in cancer.
    Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A
    Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
    Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
    Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
    Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
    Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
    Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD
    Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
    di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
    Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.